Moderna's stock (MRNA) is currently trading at $34.51 as of 2025-03-17. Based on the technical indicators:
Given the mixed technical indicators, increased short interest, and challenging market conditions for vaccine-focused companies, the stock is expected to face headwinds. However, the strong cash position and pipeline could provide support.
Prediction: MRNA stock is expected to trade between $32 and $35 next week, with a target price of $34. Considering the current technical and fundamental factors, a sell recommendation is suggested due to the bearish sentiment and short interest.
The price of MRNA is predicted to go up 4.01%, based on the high correlation periods with OUST. The similarity of these two price pattern on the periods is 96.32%.
MRNA
OUST
The stellar efficacy and safety profile of Moderna's COVID-19 vaccine offered rapid validation of the firm's mRNA technology.
Its mRNA technology could allow the firm to compete in a wide range of therapeutic areas, from other prophylactic vaccines (like influenza and other viruses) to enzyme replacement (various rare diseases) to cancer.
Moderna's cash infusion from COVID-19 vaccine sales in 2021-22, as well as newly established large-scale manufacturing facilities, position the firm to accelerate timelines for new pipeline programs.
Citigroup
2025-03-13
Price Target
$40
Upside
+16.62%
Morgan Stanley
2025-01-15
Price Target
$70 → $38
Upside
+9.29%
UBS
2025-01-08
Price Target
$108 → $96
Upside
+127.22%